Cargando…

NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION

BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Taku, Mikiko, Kobayashi, Keiichi, Yamagishi, Yuki, Saito, Kuniaki, Shimada, Daisuke, Matsumoto, Yoshie, Kikuchi, Hana, Yamada, Shin, Shiokawa, Yoshiaki, Nagane, Motoo, Okajima, Yasutomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213283/
http://dx.doi.org/10.1093/noajnl/vdz039.137
_version_ 1783531770656849920
author Taku, Mikiko
Kobayashi, Keiichi
Yamagishi, Yuki
Saito, Kuniaki
Shimada, Daisuke
Matsumoto, Yoshie
Kikuchi, Hana
Yamada, Shin
Shiokawa, Yoshiaki
Nagane, Motoo
Okajima, Yasutomo
author_facet Taku, Mikiko
Kobayashi, Keiichi
Yamagishi, Yuki
Saito, Kuniaki
Shimada, Daisuke
Matsumoto, Yoshie
Kikuchi, Hana
Yamada, Shin
Shiokawa, Yoshiaki
Nagane, Motoo
Okajima, Yasutomo
author_sort Taku, Mikiko
collection PubMed
description BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies have focused on the changes in the level of ADL and NCF in the course of PCNSL treatment, we retrospectively analyzed the effect of initial treatment of PCNSL in view of ADL and NCF. METHODS: Among 55 patients (13 male/9 female) with newly-diagnosed PCNSL treated in our institution from January 2014 to June 2019, 22 were evaluated with both ADL and NCF. Remission induction therapies consisted of high-dose methotrexate alone (two patients), R-MPV (rituximab, methotrexate, procarbazine, and vincristine)(17 patients), and R-MPV+radiaotherapy (three patients), according to the patients’ conditions. Rehabilitation staffs intervened from the beginning, providing specific exercises and periodically evaluating scores of Karnofsky Performance Status (KPS) and Mini Mental State Examination (MMSE). RESULTS: Mean age was 68.4 yo (range 34 to 85). After induction therapies, there were 11 complete responses (CRs), eight partial responses (PRs), and three progressive diseases (PDs). Both KPS and MMSE scores improved after induction therapy, from median 70 (40–90) to 80 (50–90), and from 24 (0–30) to 27(0–30), respectively. Among three patients who underwent RT, MMSE declined in two (one CR/one PR). CONCLUSIONS: Case-adjusted induction therapies resulted in significant radiographical responses, and the longitudinal evaluation of ADL and NCF by rehabilitation staffs could validate their maintenance or improvement over time through effective treatments and early rehabilitation intervention. However, three was difficulty in assessing patients with higher brain dysfunction such as aphasia and social adjustment disorder. Further study is needed to include more patients and to explore more appropriate evaluation batteries and timings during and after completion of induction therapy for PCNSL.
format Online
Article
Text
id pubmed-7213283
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72132832020-07-07 NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION Taku, Mikiko Kobayashi, Keiichi Yamagishi, Yuki Saito, Kuniaki Shimada, Daisuke Matsumoto, Yoshie Kikuchi, Hana Yamada, Shin Shiokawa, Yoshiaki Nagane, Motoo Okajima, Yasutomo Neurooncol Adv Abstracts BACKGROUNDS: Primary central nervous system lymphoma (PCNSL) frequently causes severe damage of activities of daily living (ADL) and neurocognitive function (NCF) due to extensive brain infiltration, necessitating their appropriate assessment and measures even in clinical practice. Since few studies have focused on the changes in the level of ADL and NCF in the course of PCNSL treatment, we retrospectively analyzed the effect of initial treatment of PCNSL in view of ADL and NCF. METHODS: Among 55 patients (13 male/9 female) with newly-diagnosed PCNSL treated in our institution from January 2014 to June 2019, 22 were evaluated with both ADL and NCF. Remission induction therapies consisted of high-dose methotrexate alone (two patients), R-MPV (rituximab, methotrexate, procarbazine, and vincristine)(17 patients), and R-MPV+radiaotherapy (three patients), according to the patients’ conditions. Rehabilitation staffs intervened from the beginning, providing specific exercises and periodically evaluating scores of Karnofsky Performance Status (KPS) and Mini Mental State Examination (MMSE). RESULTS: Mean age was 68.4 yo (range 34 to 85). After induction therapies, there were 11 complete responses (CRs), eight partial responses (PRs), and three progressive diseases (PDs). Both KPS and MMSE scores improved after induction therapy, from median 70 (40–90) to 80 (50–90), and from 24 (0–30) to 27(0–30), respectively. Among three patients who underwent RT, MMSE declined in two (one CR/one PR). CONCLUSIONS: Case-adjusted induction therapies resulted in significant radiographical responses, and the longitudinal evaluation of ADL and NCF by rehabilitation staffs could validate their maintenance or improvement over time through effective treatments and early rehabilitation intervention. However, three was difficulty in assessing patients with higher brain dysfunction such as aphasia and social adjustment disorder. Further study is needed to include more patients and to explore more appropriate evaluation batteries and timings during and after completion of induction therapy for PCNSL. Oxford University Press 2019-12-16 /pmc/articles/PMC7213283/ http://dx.doi.org/10.1093/noajnl/vdz039.137 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Taku, Mikiko
Kobayashi, Keiichi
Yamagishi, Yuki
Saito, Kuniaki
Shimada, Daisuke
Matsumoto, Yoshie
Kikuchi, Hana
Yamada, Shin
Shiokawa, Yoshiaki
Nagane, Motoo
Okajima, Yasutomo
NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title_full NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title_fullStr NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title_full_unstemmed NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title_short NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION
title_sort nqpc-06 functional outcomes of initial treatments for patients with primary central nervous system lymphoma assessed by adl and neurocognitive function
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213283/
http://dx.doi.org/10.1093/noajnl/vdz039.137
work_keys_str_mv AT takumikiko nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT kobayashikeiichi nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT yamagishiyuki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT saitokuniaki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT shimadadaisuke nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT matsumotoyoshie nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT kikuchihana nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT yamadashin nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT shiokawayoshiaki nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT naganemotoo nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction
AT okajimayasutomo nqpc06functionaloutcomesofinitialtreatmentsforpatientswithprimarycentralnervoussystemlymphomaassessedbyadlandneurocognitivefunction